Apollomics (APLM) Debt Ratio (2023 - 2025)

Apollomics (APLM) posted quarterly Debt Ratio of 0.45 for Q4 2025, up 24.39% on a QoQ basis from 0.36 in Q2 2025.

Apollomics (APLM) Debt Ratio (2023 - 2025) Analysis & Trends

Apollomics (APLM) has reported Debt Ratio for 3 consecutive years, with 0.45 the latest figure, recorded in Q4 2025.

  • Quarterly Debt Ratio changed N/A year-over-year to 0.45 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 0.45 (changed N/A YoY) and the FY2025 annual result came in at 0.45, changed N/A from the prior year.
  • Debt Ratio advanced to 0.45 in Q4 2025 per APLM's latest filing, from 0.36 in the prior quarter.
  • Over the last five years, Debt Ratio for APLM reached as high as 0.45 in Q4 2025 and fell as low as 0.1 in Q4 2023.
  • A 3-year average of 0.27 and a median of 0.26 in 2025 frame the typical range for Debt Ratio.
  • The largest YoY upside for Debt Ratio was 114.34% in 2025 against a maximum downside of 114.34% in 2025.
  • Year by year, Debt Ratio stood at 0.1 in 2023, then soared by 64.12% to 0.17 in 2024, then soared by 166.62% to 0.45 in 2025.
  • According to Business Quant data, Debt Ratio over the past three periods registered 0.45, 0.36, and 0.17 for Q4 2025, Q2 2025, and Q2 2024 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Debt Ratio (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - 1.41
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 0.11
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn -
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn 0.05
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 Apollomics 2.66 Bn 2.66 Bn - 0.45

Historic Data

Download Data
DateValue
Dec 31, 2025 0.45
Jun 30, 2025 0.36
Jun 30, 2024 0.17
Dec 31, 2023 0.10